Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis

详细信息	查看全文 | 推荐本文 |

• 作者：John P. Caloyeras ; MPhil¹ ; ² ; ^{jcaloyer@prgs.edu} ; Bin Zhang ; MD ; MSc¹ ; Cheng Wang ; MD ; PhD³ ; Marianne Eriksson ; MSc⁴ ; Sten Fredrikson ; MD ; PhD⁵ ; Karola Beckmann ; MSc⁶ ; Volker Knappertz ; MD³ ; Christoph Pohl ; MD⁶ ; ⁷ ; Hans-Peter Hartung ; MD⁸ ; Dhvani Shah ; MS⁹ ; Jeffrey D. Miller ; MS¹ ; Rupert Sandbrink ; MD⁶ ; ⁸ ; Vivian Lanius ; PhD⁶ ; Kathleen Gondek ; PhD³ ; Mason W. Russell ; MAPE¹
• 关键词：BENEFIT trial ; cost effectiveness ; interferon 尾-1b ; multiple sclerosis ; Sweden
• 刊名：Clinical Therapeutics
• 出版年：2012
• 期刊代码：65_01492918
• 类别：med
• 出版时间：May, 2012
• 卷：34
• 期：5
• 页码：1132-1144
• 文件大小：882 K

摘要

Objectives

To assess, from a Swedish societal perspective, the cost effectiveness of interferon 尾-1b (IFNB-1b) after an initial clinical event suggestive of multiple sclerosis (MS) (ie, early treatment) compared with treatment after onset of clinically definite MS (CDMS) (ie, delayed treatment).

Methods

A Markov model was developed, using patient level data from the BENEFIT trial and published literature, to estimate health outcomes and costs associated with IFNB-1b for hypothetical cohorts of patients after an initial clinical event suggestive of MS. Health states were defined by Kurtzke Expanded Disability Status Scale (EDSS) scores. Model outcomes included quality-adjusted life years (QALYs), total costs (including both direct and indirect costs), and incremental cost-effectiveness ratios. Sensitivity analyses were performed on key model parameters to assess the robustness of model results.

Results

In the base case scenario, early IFNB-1b treatment was economically dominant (ie, less costly and more effective) versus delayed IFNB-1b treatment when QALYs were used as the effectiveness metric. Sensitivity analyses showed that the cost-effectiveness results were sensitive to model time horizon. Compared with the delayed treatment strategy, early treatment of MS was also associated with delayed EDSS progressions, prolonged time to CDMS diagnosis, and a reduction in frequency of relapse.

Conclusion

Early treatment with IFNB-1b for a first clinical event suggestive of MS was found to improve patient outcomes while controlling costs.